Immunotoxins and Cancer Therapy  

作　　者：ZhengLi TaoYu PingZhao JieMa 

机构地区：[1]StateKeyLaboratoryofMolecularOncology.CancerInstitute＆Hospital,ChineseAcademyofMedicalSciences.PUMC,Beijing0002.Chna： [2]DepartmentofMedicine.PUMC,Beijing100006.China [3]DepartmentofSurgery,CancerInstitute＆Hospital,ChineseAcademyofMedicalSciences,PUMC,Beijing100021,China [4]Correspondingto：Dr.JieMa,StateKeyLaboratoryofMolecularOncology.CancerInstitute＆Hospital,ChineseAcademyofMedicalSciences.PUMC.Beijing100021.China.

出　　处：《Cellular & Molecular Immunology》2005年第2期106-112,共7页中国免疫学杂志（英文版）

摘　　要：In the past decade,an increased amount of clinicallyloriented research involving immunotoxins has been published. Immunotoxins are a group of artificially-made cytotoxic molecules targeting cancer cells.These molecules composed of a targeting moiety,such as a ligand or an antibody,linked to toxin moiety,which is a toxin with either truncated or deleted cell-binding domain that prevents it from binding to normal cells.Immunotoxins can be divided into two categories:chemically conjugated immunotoxins and recombinant ones.The immunotoxins of the first category have shown limited efficacy in clinical trials in patients with hematologic malignancies and solid tumors.Within the last few years,single-chain immunotoxins provide enhanced therapeutic efficacy over conjugated forms and result in improved antitumor activity.In this review,we briefly illustrate the design of the immunotoxins and their applications in clinical trials.Cellular & Molecular Immunology.2005;2(2):106-112.In the past decade,an increased amount of clinicallyloriented research involving immunotoxins has been published. Immunotoxins are a group of artificially-made cytotoxic molecules targeting cancer cells.These molecules composed of a targeting moiety,such as a ligand or an antibody,linked to toxin moiety,which is a toxin with either truncated or deleted cell-binding domain that prevents it from binding to normal cells.Immunotoxins can be divided into two categories:chemically conjugated immunotoxins and recombinant ones.The immunotoxins of the first category have shown limited efficacy in clinical trials in patients with hematologic malignancies and solid tumors.Within the last few years,single-chain immunotoxins provide enhanced therapeutic efficacy over conjugated forms and result in improved antitumor activity.In this review,we briefly illustrate the design of the immunotoxins and their applications in clinical trials.Cellular & Molecular Immunology.2005;2(2):106-112.

关 键 词：IMMUNOTOXIN cancer therapy Pseudomonas exotoxin SCFV 

分 类 号：R730.51[医药卫生—肿瘤]